Abstract: Objective To investigate the efficacy and side effects of docetaxel based regimens as the secondline chemotherapy in osteosarcoma with lung metastasis. Methods From January 2012 to December 2013， 11 osteosarcoma patients with lung metastasis whom failed from firstline chemotherapy were taken docetaxel（75 mg/m², d₈） combined with gemcitabine（675 mg/m², d₁, d₈）／platinum（30 mg/m², d₂） as the second-line chemotherapy. 21 days was a cycle. The firstline chemotherapy contained cisplatin， ifosfamide， adriamycin methotrexate alternating scheme. The efficacy was evaluated by RECIST 1.0 criterion， and side effects were recorded by NCI-CTC 3.0 criterion. Results All patients finished treatment， and could be evaluated. There was no complete remission （CR） case， partial remission （PR） in 1 case， stable disease （SD） in 4 cases， progression of disease （PD） in 6 cases； and the response rate（RR） was 9.1％， disease control rate （DCR） was 45.5％. During the follow-up period， 3 patients died. The median progression free survival time was 10.5 months， the median overall survival time was 18.0 months， and 1-year survival rate was 83.3％. The major adverse reactions were limiting myelosuppression during chemotherapy. There was no patients with renal dysfunction and allergic reaction， grade 4 neutropenia and thrombocytopenia was occured in 1 case.
Conclusion Docetaxel based regimen is effective as the secondline chemotherapy in osteosarcoma with lung metastasis， and the shortterm curative effect is satisfactory， toxicity can be tolerated.